Global Medical Device Company Expands Deployment of BIO-key Biometric Authentication to Streamline Employee Training

WALL, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that its long-time customer, global medical device manufacturer ICU Medical, Inc., has expanded its use of BIO-key biometric authentication to its new staff training program, streamlining check-in and automating FDA compliance recordkeeping.
ICU Medical has been successfully using BIO-key biometric authentication solutions since 2005, initially to streamline and automate an FDA-regulated Quality Control (QC) signoff process within Oracle ERP during product manufacturing. This lean-process innovation shaved significant time off the production of their infusion products while ensuring in real-time that the signing QC staff member was properly authorized and trained to perform the specific QC process, compliant with Code of Federal Regulations (CFR) 21 part 11.As ICU Medical has grown over the past 15 years, BIO-key biometric authentication has enabled the company to seamlessly add users and worldwide locations without having to buy, issue, or track any physical tokens for each staff member. The integration of BIO-key has greatly simplified ICU Medical’s onboarding and offboarding process.Recently, ICU Medical wanted to add a secure, user-friendly method to authenticate access to iLearning, a staff training platform from Seertech that incorporates content, accounting, and reporting functions. They leveraged the existing successful BIO-key authentication platform for a larger group of users and are seeing the benefits in terms of faster training sign-ins, simplified accounting, and a better user experience.“We are thrilled to see ICU Medical finding new ways to streamline operations using their investment in BIO-key’s one-touch, strong authentication,” stated Jim Sullivan, BIO-key SVP of Strategy and Chief Legal Officer. “By adding BIO-key efficiency to their digital learning initiatives, the company simplified the process of maintaining its training requirements, while providing its employees with the tools to make their jobs easier.”About BIO-key International, Inc. (www.bio-key.com)
BIO-key is revolutionizing authentication with biometric solutions that enable convenient and secure access to devices, information, applications, and high-value transactions. BIO-key’s software and hardware finger scanning solutions offer secure, user-friendly, and attractively priced alternatives to passwords, PINs, tokens, and security cards, enabling enterprises and consumers to secure their networks and devices as well as their information in the cloud.BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Additionally, there may be other factors of which the company is not currently aware that may affect matters discussed in forward-looking statements and may also cause actual results to differ materially from those discussed. In particular, the consequences of the coronavirus outbreak to economic conditions and the industry in general and the financial position and operating results of our company in particular have been material, are changing rapidly, and cannot be predicted.Investor & Media Contacts
William Jones, David Collins
Catalyst IR
212-924-9800
bkyi@catalyst-ir.com